Title (en)

NS3728 FOR USE IN COMBINATION WITH TEMOZOLOMIDE FOR THE TREATMENT OF GLIOBLASTOMA

Title (de)

NS3728 IN KOMBINATION MIT TEMOZOLOMID ZUR BEHANDLUNG VON GLIOBLASTOM

Title (fr)

NS3728 EN COMBINAISON AVEC DU TEMOZOLOMIDE POUR LE TRAITEMENT DU GLIOBLASTOME

Publication

EP 3854393 A1 20210728 (EN)

Application

EP 21162597 A 20170517

Priority

- DK PA201670325 A 20160517
- EP 19205104 A 20170517
- EP 17726573 A 20170517
- EP 2017061823 W 20170517

Abstract (en)

The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

IPC 8 full level

A61K 31/4245 (2006.01); **A61K 31/41** (2006.01); **A61K 31/4745** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **C07D 257/04** (2006.01); **C07D 271/07** (2006.01)

CPC (source: EP US)

A61K 31/138 (2013.01 - US); **A61K 31/337** (2013.01 - US); **A61K 31/41** (2013.01 - EP US); **A61K 31/4745** (2013.01 - EP US); **A61K 31/495** (2013.01 - US); **A61K 31/513** (2013.01 - US); **A61K 31/566** (2013.01 - US); **A61K 33/243** (2018.12 - US); **A61K 45/06** (2013.01 - EP); **A61P 1/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP US); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 257/04** (2013.01 - EP US)

C-Set (source: EP US)

1. **A61K 31/41** + **A61K 2300/00**
2. **A61K 31/4745** + **A61K 2300/00**

Citation (applicant)

- WO 9847879 A1 19981029 - NEUROSEARCH AS [DK], et al
- WO 0024707 A1 20000504 - NEUROSEARCH AS [DK], et al
- WO 2004012733 A2 20040212 - NEUROSEARCH AS [DK], et al
- EP 2919009 A1 20150916 - MAX DELBRÜCK CT FÜR MOLEKULARE MEDIZIN MDC [DE], et al
- HELIX ET AL., J. MEMBRANE BIOL., vol. 196, 2003
- POULSEN ET AL., AM J PHYSIOL CELL PHYSIOL, 2010
- SORENSEN ET AL., AM J PHYSIOL CELL PHYSIOL, 2016
- PLANELLS_CASES, R ET AL., EMBO J., 2015
- VOSS ET AL., SCIENCE, vol. 344, no. 6184, 2014, pages 634 - 8
- QUI ET AL., CELL, vol. 157, no. 2, 2014, pages 447 - 58
- KORSGAARD, MP ET AL., COMB CHEM HIGH TROUGHPUT SCREEN, 2009
- CHAMBERS, C ET AL., ASSAY DRUG DEV TECHNOL., 2016
- HELIX ET AL., J MEMBRANE BIOL, vol. 196, 2003
- LICHTENBERG, J.P.J. HJARNAAP.E. KRISTJANSEND. HANSENL. BINDERUP: "The rat subcutaneous air sac mode: A quantitative assay of antiangiogenesis in induced vessels", PHARMACOLOGY & TOXICOLOGY, vol. 84, 1999, pages 34 - 40

Citation (search report)

- [X] EP 1526851 A2 20050504 - NEUROSEARCH AS [DK]
- [A] DAVID A REARDON ET AL: "Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma", JOURNAL OF NEURO-ONCOLOGY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 101, no. 1, 5 May 2010 (2010-05-05), pages 57 - 66, XP019866326, ISSN: 1573-7373, DOI: 10.1007/S11060-010-0217-6

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017198700 A1 20171123; AU 2017266724 A1 20181220; AU 2017266724 B2 20220414; BR 112018073518 A2 20190319; CA 3023202 A1 20171123; CN 109475535 A 20190315; CY 1122541 T1 20210127; CY 1124242 T1 20220722; DK 3458052 T3 20200203; DK 3622953 T3 20210426; EP 3458052 A1 20190327; EP 3458052 B1 20191106; EP 3622953 A1 20200318; EP 3622953 B1 20210317; EP 3854393 A1 20210728; ES 2770374 T3 20200701; ES 2870805 T3 20211027; HR P20200076 T1 20200403; HR P20210572 T1 20210514; HU E047542 T2 20200428; HU E053744 T2 20210728; JP 2019519506 A 20190711; JP 7033554 B2 20220310; LT 3458052 T 20200210; LT 3622953 T 20210426; PL 3458052 T3 20200629; PL 3622953 T3 20210816; PT 3458052 T 20200203; PT 3622953 T 20210421; RS 59844 B1 20200228; RS 61786 B1 20210630; SI 3458052 T1 20200430; SI 3622953 T1 20210531; US 11103481 B2 20210831; US 11903927 B2 20240220; US 2019269654 A1 20190905; US 2021353596 A1 20211118

DOCDB simple family (application)

EP 2017061823 W 20170517; AU 2017266724 A 20170517; BR 112018073518 A 20170517; CA 3023202 A 20170517; CN 201780043536 A 20170517; CY 201100070 T 20200127; CY 211100332 T 20210415; DK 17726573 T 20170517; DK 19205104 T 20170517; EP 17726573 A 20170517; EP 19205104 A 20170517; EP 21162597 A 20170517; ES 17726573 T 20170517; ES 19205104 T 20170517; HR P20200076 T 20200117; HR P20210572 T 20210409; HU E17726573 A 20170517; HU E19205104 A 20170517; JP 2018560218 A 20170517; LT 17726573 T 20170517; LT 19205104 T 20170517; PL 17726573 T 20170517; PL 19205104 T 20170517; PT 17726573 T 20170517;

PT 19205104 T 20170517; RS P20200088 A 20170517; RS P20210510 A 20170517; SI 201730169 T 20170517; SI 201730713 T 20170517; US 201716302195 A 20170517; US 202117388208 A 20210729